American Society of Hematology 2016 – Day 3

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

The American Society of Hematology meeting is filled with the latest data on hematology, both benign and malignant, but there is also a lot of talk about the number of steps one walks during a single day, often over 20,000.

Day 3 started early with 6 oral abstracts focused on the latest data on CLL. While my interviews took place much later in the day and the following day, I would like to share my thoughts on those presentations:

Day 3 ended on a high note with me standing in front of our poster presentation based on the survey we did on patient preferences for treatment and where patients go for information. Here is my commentary.

If you want to read more about the abstracts from the oral session, they include:

Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib

Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study

Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL:  Preliminary Results of a Multicenter Phase I/Ib Study

CLL2-BIG – a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

More to come.

Brian Koffman, MD 12/8/16